Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Complementary Immunometabolic Effects of Exercise and PPARβ/δ Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice. 31635041 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Previous investigations have shown that the peroxisome proliferator activated receptor beta/delta (PPAR<beta>/<delta>)-angiopoietin-like protein 4 (ANGPTL4) pathways may be a new pharmacologic target for treatment of obesity. 28320596 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE The nuclear hormone receptor peroxisome proliferator-activated receptor delta (PPARδ) is a ligand-dependent transcription factor involved in fatty acid metabolism, obesity, wound healing, inflammation, and cancer. 31239272 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE PPARβ/δ activation might help prevent the development of metabolic disorders, including obesity, dyslipidaemia, type 2 diabetes mellitus and non-alcoholic fatty liver disease. 29558390 2018
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE Regarding new generation drugs, acting on both α/γ, β/δ, or α/δ receptors simultaneously, preliminary data on PPAR-α/γ dual agonists revealed a positive effect on lipid profile, blood pressure, atherosclerosis, inflammation, and anti-coagulant effects, while the overexpression of PPAR-β/δ seems to prevent obesity and to decrease lipid storage in cardiac cells. 28098353 2018
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE These results suggest that G. frondosa is a novel functional food that may prevent life-style related diseases like obesity and diabetes, and that these beneficial effects are likely to be mediated through the activation of PPARδ and a PPARδ-independent insulin signaling pathway. 29873587 2018
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Using mice with an intestinal epithelial cell-specific deletion of PPARδ, we show that intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia. 28404991 2017
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Accumulated evidence suggests that the polymorphism rs2016520 in PPARD is associated with lipid metabolism, obesity, metabolic syndrome, and type 2 diabetes mellitus. 28128413 2017
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE We aimed at investigating the influence of obesity on sirtuins' levels, their role in obesity-associated inflammation, and the relationship with the peroxisome proliferator-activated receptor delta, which also plays functions in adipose tissue metabolism. 27844208 2017
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE To investigate the association of haplotypes of PPAR δ gene rs2016520 and rs9794 with abnormal weight (BMI ≥ 24 kg/m(2)) and abdominal obesity (WC ≥ 90 cm for males and ≥ 80 cm for females) in a Chinese Han population. 26073637 2016
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Polymorphism of rs2016520 in gene PPARD has been associated with lipid metabolism, obesity, metabolic syndrome and type 2 diabetes mellitus (T2DM). 26915488 2016
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE This study aimed to investigate the association of peroxisome proliferator-activated receptor (PPAR) genes PPARα L162V, PPARγ2 C161T and PPARδ T294C single nucleotide polymorphisms (SNPs) with obesity and metabolic syndrome (Met-S) in a multi-ethnic population in Kampar, Malaysia. 26673968 2015
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Our population and ethnic-based study demonstrates that the PPARδ +294C allele maybe an independent risk of IS in Chinese Uyghurs especially in the male (OR 1.99, 95%CI:1.06-3.72) and obesity populations (OR 2.36, 95%CI: 1.19-4.67), which were consistent with Tunisian Population. 26346611 2015
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE Peroxisome proliferator-activated receptor-β/δ (PPARδ) is a ubiquitously expressed, ligand-activated transcriptional factor that performs diverse critical functions in normal cells (e.g., fatty acid metabolism, obesity, apoptosis, and inflammation). 23041232 2013
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Gene-gene interaction between PPARδ and PPARγ is associated with abdominal obesity in a Chinese population. 23273766 2012
CUI: C0028754
Disease: Obesity
Obesity
0.400 Therapeutic disease CTD_human Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. 20176998 2010
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity. 20200337 2010
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Genetic association studies of single-nucleotide polymorphisms in the PPARD gene have only provided negative or conflicting evidence for gross phenotypes such as obesity, hyperlipidaemia and type 2 diabetes. 19512923 2009
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE In addition, we have found a significant interaction between CAPN5 and PPARD genes (p = 0.038) that reduces the risk for obesity in a 55%. 18657264 2008
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Our study reveals a novel mechanism by which PPARdelta regulates lipogenesis, suggesting potential therapeutic applications of PPARdelta modulators in obesity and type 2 diabetes, as well as related steatotic liver diseases. 18627005 2008
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Moreover, PPARdelta augments physical endurance and increases oxidative metabolism, thereby averting obesity. 17431579 2007
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Peroxisome proliferator-activated receptor-delta (PPARdelta) is a nuclear receptor implicated in lipid oxidation and the pathogenesis of obesity and diabetes. 16966336 2006
CUI: C0028754
Disease: Obesity
Obesity
0.400 Therapeutic disease CTD_human Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. 16168052 2005
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE The results of recent studies using selective agonists for peroxisome proliferator-activated receptor beta (PPARbeta) suggest that this receptor may have a role in regulating levels of serum lipids in animal models of obesity and insulin resistance. 15001574 2004